X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs GLENMARK PHARMA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER GLENMARK PHARMA PFIZER/
GLENMARK PHARMA
 
P/E (TTM) x 24.2 14.1 171.7% View Chart
P/BV x 3.8 3.9 97.4% View Chart
Dividend Yield % 0.8 0.3 261.7%  

Financials

 PFIZER   GLENMARK PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-16
GLENMARK PHARMA
Mar-16
PFIZER/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs2,7241,262 215.8%   
Low Rs1,611672 239.9%   
Sales per share (Unadj.) Rs440.9270.6 163.0%  
Earnings per share (Unadj.) Rs48.724.9 195.7%  
Cash flow per share (Unadj.) Rs75.834.4 220.2%  
Dividends per share (Unadj.) Rs15.002.00 750.0%  
Dividend yield (eoy) %0.70.2 334.5%  
Book value per share (Unadj.) Rs462.9151.3 305.9%  
Shares outstanding (eoy) m45.75282.16 16.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.93.6 137.6%   
Avg P/E ratio x44.538.9 114.5%  
P/CF ratio (eoy) x28.628.1 101.8%  
Price / Book Value ratio x4.76.4 73.3%  
Dividend payout %30.88.0 383.1%   
Avg Mkt Cap Rs m99,163272,778 36.4%   
No. of employees `0002.910.0 28.8%   
Total wages/salary Rs m2,75813,782 20.0%   
Avg. sales/employee Rs Th6,981.77,614.9 91.7%   
Avg. wages/employee Rs Th954.51,374.8 69.4%   
Avg. net profit/employee Rs Th771.1700.2 110.1%   
INCOME DATA
Net Sales Rs m20,17076,340 26.4%  
Other income Rs m857356 240.7%   
Total revenues Rs m21,02876,696 27.4%   
Gross profit Rs m4,31014,172 30.4%  
Depreciation Rs m1,2392,691 46.0%   
Interest Rs m51,789 0.3%   
Profit before tax Rs m3,92310,048 39.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m990-   
Tax Rs m1,7943,028 59.3%   
Profit after tax Rs m2,2287,019 31.7%  
Gross profit margin %21.418.6 115.1%  
Effective tax rate %45.730.1 151.7%   
Net profit margin %11.09.2 120.1%  
BALANCE SHEET DATA
Current assets Rs m16,29959,096 27.6%   
Current liabilities Rs m7,59440,018 19.0%   
Net working cap to sales %43.225.0 172.7%  
Current ratio x2.11.5 145.3%  
Inventory Days Days6575 87.1%  
Debtors Days Days26119 21.6%  
Net fixed assets Rs m8,62239,075 22.1%   
Share capital Rs m458282 162.1%   
"Free" reserves Rs m20,72230,281 68.4%   
Net worth Rs m21,18042,703 49.6%   
Long term debt Rs m2524,873 0.1%   
Total assets Rs m29,137111,026 26.2%  
Interest coverage x755.56.6 11,418.0%   
Debt to equity ratio x00.6 0.2%  
Sales to assets ratio x0.70.7 100.7%   
Return on assets %7.77.9 96.6%  
Return on equity %10.516.4 64.0%  
Return on capital %19.017.5 108.4%  
Exports to sales %0.143.3 0.1%   
Imports to sales %17.57.4 235.2%   
Exports (fob) Rs m1233,044 0.0%   
Imports (cif) Rs m3,5265,672 62.2%   
Fx inflow Rs m5236,945 0.1%   
Fx outflow Rs m14061,066 0.2%   
Net fx Rs m-88-24,122 0.4%   
CASH FLOW
From Operations Rs m3,4363,449 99.6%  
From Investments Rs m-6,991-8,802 79.4%  
From Financial Activity Rs m-6196,986 -8.9%  
Net Cashflow Rs m-4,174934 -446.9%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 6.9 108.7%  
FIIs % 4.9 34.4 14.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 10.5 225.7%  
Shareholders   85,207 56,727 150.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   DR. REDDYS LAB  STERLING BIOTECH  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  IPCA LABS  

Compare PFIZER With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Bank Stocks Witness Selling(01:30 pm)

After opening the day on a flat note, the Indian share markets have reversed the trend and are currently trading above the dotted line.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Aug 17, 2017 02:13 PM

TRACK PFIZER

PFIZER - CLARIS LIFESCIENCES COMPARISON

COMPARE PFIZER WITH

MARKET STATS